<?xml version='1.0' encoding='utf-8'?>
<document id="19223624"><sentence text="Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine."><entity charOffset="37-46" id="DDI-PubMed.19223624.s1.e0" text="efavirenz" /><entity charOffset="98-111" id="DDI-PubMed.19223624.s1.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.19223624.s1.e0" e2="DDI-PubMed.19223624.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19223624.s1.e0" e2="DDI-PubMed.19223624.s1.e1" /></sentence><sentence text="Characterization of the time course and magnitude of enzyme induction due to multiple inducers is important for interpretation of clinical data from drug-drug interaction studies" /><sentence text=" A population interaction model was developed to quantify efavirenz autoinduction and further induction with concurrent carbamazepine coadministration"><entity charOffset="58-67" id="DDI-PubMed.19223624.s3.e0" text="efavirenz" /><entity charOffset="120-133" id="DDI-PubMed.19223624.s3.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.19223624.s3.e0" e2="DDI-PubMed.19223624.s3.e0" /><pair ddi="false" e1="DDI-PubMed.19223624.s3.e0" e2="DDI-PubMed.19223624.s3.e1" /></sentence><sentence text=" Efavirenz concentration data in the absence and presence of carbamazepine following single- and multiple-dose oral administrations in healthy subjects were used for model development"><entity charOffset="1-10" id="DDI-PubMed.19223624.s4.e0" text="Efavirenz" /><entity charOffset="61-74" id="DDI-PubMed.19223624.s4.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.19223624.s4.e0" e2="DDI-PubMed.19223624.s4.e0" /><pair ddi="false" e1="DDI-PubMed.19223624.s4.e0" e2="DDI-PubMed.19223624.s4.e1" /></sentence><sentence text=" The proposed model was able to describe the time-dependent efavirenz autoinduction and the further induction with carbamazepine when the agents were combined"><entity charOffset="60-69" id="DDI-PubMed.19223624.s5.e0" text="efavirenz" /><entity charOffset="115-128" id="DDI-PubMed.19223624.s5.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.19223624.s5.e0" e2="DDI-PubMed.19223624.s5.e0" /><pair ddi="false" e1="DDI-PubMed.19223624.s5.e0" e2="DDI-PubMed.19223624.s5.e1" /></sentence><sentence text=" The estimated population averages of efavirenz oral clearance were 5"><entity charOffset="38-47" id="DDI-PubMed.19223624.s6.e0" text="efavirenz" /></sentence><sentence text="5, 9" /><sentence text="4, 14" /><sentence text="4, and 16" /><sentence text="7 liters/h on days 1, 14, and 35 and at steady state for the interaction, respectively, for efavirenz monotherapy for 2 weeks followed by the coadministration of carbamazepine for 3 weeks"><entity charOffset="92-101" id="DDI-PubMed.19223624.s10.e0" text="efavirenz" /><entity charOffset="162-175" id="DDI-PubMed.19223624.s10.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.19223624.s10.e0" e2="DDI-PubMed.19223624.s10.e0" /><pair ddi="false" e1="DDI-PubMed.19223624.s10.e0" e2="DDI-PubMed.19223624.s10.e1" /></sentence><sentence text=" The estimated times to 50% of the steady state for efavirenz autoinduction and for the induction resulting from the concurrent administration of efavirenz and carbamazepine were similar (around 10 to 12 days)"><entity charOffset="52-61" id="DDI-PubMed.19223624.s11.e0" text="efavirenz" /><entity charOffset="146-155" id="DDI-PubMed.19223624.s11.e1" text="efavirenz" /><entity charOffset="160-173" id="DDI-PubMed.19223624.s11.e2" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.19223624.s11.e0" e2="DDI-PubMed.19223624.s11.e0" /><pair ddi="false" e1="DDI-PubMed.19223624.s11.e0" e2="DDI-PubMed.19223624.s11.e1" /><pair ddi="false" e1="DDI-PubMed.19223624.s11.e0" e2="DDI-PubMed.19223624.s11.e2" /><pair ddi="false" e1="DDI-PubMed.19223624.s11.e1" e2="DDI-PubMed.19223624.s11.e1" /><pair ddi="false" e1="DDI-PubMed.19223624.s11.e1" e2="DDI-PubMed.19223624.s11.e2" /></sentence><sentence text=" With this model-based analysis, efavirenz exposures can be projected prior to and at the steady state of induction, allowing a better understanding of the time course and magnitude of enzyme induction"><entity charOffset="33-42" id="DDI-PubMed.19223624.s12.e0" text="efavirenz" /></sentence><sentence text="" /></document>